ALX Oncology reports Q3 2026 results, sets December data for ALX2004
The company said it expects ALX2004 Phase 1 safety and early efficacy data in December 2026 and ASPEN-09-Breast topline results in the second half of 2027.
ALX Oncology Holdings Inc. reported financial results for the third quarter ended September 30, 2026, and provided a corporate update on November 16, 2026.
The company said dose-escalation safety and early efficacy data from the ongoing ALX2004 Phase 1 clinical trial (NCT07085091) are expected in December 2026, with a planned KOL webinar to review results from 35 patients enrolled to date.1 That trial is described as a first-in-human, open-label, multicenter study in patients with advanced or metastatic EGFR-expressing solid tumors.1
On evorpacept, ALX Oncology said enrollment in the ongoing ASPEN-09-Breast Phase 2 trial, evaluating evorpacept in combination with trastuzumab and chemotherapy, remains on track, with topline data from 120 patients expected in the second half of 2027.1 In September the company announced publication of ASPEN-06 Phase 2 data in Nature Medicine, a randomized trial in HER2-positive gastric and gastroesophageal junction cancers; the study showed improved response rates versus the control arm, with the greatest benefit seen in patients whose tumors retained HER2 expression and also had high CD47 expression.1 The company said these findings support CD47 as a potential predictive biomarker and reinforce its biomarker-driven development strategy, including the ongoing ASPEN-09-Breast trial.1
On finances, cash, cash equivalents and investments were $147.2 million as of September 30, 2026, which the company believes is sufficient to fund planned operations through the first half of 2028.1 GAAP net loss was $21.8 million, or $0.15 per share, for the quarter, compared with a $22.1 million loss, or $0.41 per share, in the prior-year period.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.